OIPE AND W

AP/BFW

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC

Under Panerwork Reduction Act of 199	5. no persor	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ans are required to respond to a collection of information unless it displays a valid OMB control number.				
		Application Number	10/729,499  December 5, 2003  Elfatih Elzein			
TRANSMITTAL		Filing Date				
FORM		First Named Inventor				
		Art Unit				
o be used for all correspondence after initia	l filing)	Examiner Name				
	1./	Attorney Docket Number	02-175			

ENCLOSURES (Check all that apply)											
	Fee Trans	mittal Fo	rm		Drawing(s)				After A	Ilowance Communication to TC	
		e Attach			Licensing-re	ated Papers				Communication to Board eals and Interferences	
	Extension Express A Informatio  Certified C Document Reply to M Incomplete	ter Final fidavits/d of Time abandonr on Disclos Copy of P t(s) Aissing P e Applica eply to M	eclaration(s) Request ment Request sure Statement triority arts/	Rem	Change of C Terminal Dis Request for CD, Number	Application orney, Revoca orrespondence claimer Refund	e Address	1 *	(Appea Proprie Status Other below) es of re	Enclosure(s) (please Identify	
			SIGNA	TURE	OF APPLI	CANT, AT	ORNEY, C	OR AG	ENT		
Firm Name CV Therapeutics, Inc.											
Signat	ure		15,			_					
Printed	d name	J. Elin	Hartrum	O							
Date		June 1	, 2006			<u></u>	Reg. No.	43,66	3		
CERTIFICATE OF TRANSMISSION/MAILING											
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:											
Signat	ure		Susa	ر ا	ahea	in					
Typed	or printed r	name	Susan Ahear						Date	06/01/2006	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Elzein et al.

Confirmation No.: 8126

Serial No.: 10/729,499

Group Art Unit: 1624

Filing Date: December 5, 2003

Examiner: Bernhardt, Emily B.

Title: Substituted Heterocyclic Compounds

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria VA, 22313-1450

## AMENDMENT UNDER 37 CFR § 1.116

In response to the Final Office Action of April 6, 2006, please amend the above-identified application as follows.

Amendments to the Claims are reflected in the listing of the claims that begins on page 2 of this paper.

Remarks begin on page 6 of this paper.